172 related articles for article (PubMed ID: 33588149)
1. A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.
Vidal L; Victoria I; Gaba L; Martín MG; Brunet M; Colom H; Cortal M; Gómez-Ferrería M; Yeste-Velasco M; Perez A; Rodon J; Sohal DPS; Lizcano JM; Domènech C; Alfón J; Gascón P
Eur J Cancer; 2021 Mar; 146():87-94. PubMed ID: 33588149
[TBL] [Abstract][Full Text] [Related]
2. The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.
Muñoz-Guardiola P; Casas J; Megías-Roda E; Solé S; Perez-Montoyo H; Yeste-Velasco M; Erazo T; Diéguez-Martínez N; Espinosa-Gil S; Muñoz-Pinedo C; Yoldi G; Abad JL; Segura MF; Moran T; Romeo M; Bosch-Barrera J; Oaknin A; Alfón J; Domènech C; Fabriàs G; Velasco G; Lizcano JM
Autophagy; 2021 Jun; 17(6):1349-1366. PubMed ID: 32397857
[TBL] [Abstract][Full Text] [Related]
3. The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis.
París-Coderch L; Soriano A; Jiménez C; Erazo T; Muñoz-Guardiola P; Masanas M; Antonelli R; Boloix A; Alfón J; Pérez-Montoyo H; Yeste-Velasco M; Domènech C; Roma J; Sánchez de Toledo J; Moreno L; Lizcano JM; Gallego S; Segura MF
Cell Death Dis; 2020 Sep; 11(9):773. PubMed ID: 32943619
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Felip I; Moiola CP; Megino-Luque C; Lopez-Gil C; Cabrera S; Solé-Sánchez S; Muñoz-Guardiola P; Megias-Roda E; Pérez-Montoyo H; Alfon J; Yeste-Velasco M; Santacana M; Dolcet X; Reques A; Oaknin A; Rodríguez-Freixinos V; Lizcano JM; Domènech C; Gil-Moreno A; Matias-Guiu X; Colas E; Eritja N
Gynecol Oncol; 2019 May; 153(2):425-435. PubMed ID: 30853360
[TBL] [Abstract][Full Text] [Related]
5. The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.
López-Plana A; Fernández-Nogueira P; Muñoz-Guardiola P; Solé-Sánchez S; Megías-Roda E; Pérez-Montoyo H; Jauregui P; Yeste-Velasco M; Gómez-Ferreria M; Erazo T; Ametller E; Recalde-Percaz L; Moragas-Garcia N; Noguera-Castells A; Mancino M; Morán T; Nadal E; Alfón J; Domènech C; Gascon P; Lizcano JM; Fuster G; Bragado P
Int J Cancer; 2020 Aug; 147(4):1163-1179. PubMed ID: 31943158
[TBL] [Abstract][Full Text] [Related]
6. Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.
Mancini A; Colapietro A; Cristiano L; Rossetti A; Mattei V; Gravina GL; Perez-Montoyo H; Yeste-Velasco M; Alfon J; Domenech C; Festuccia C
Front Oncol; 2022; 12():943064. PubMed ID: 36408162
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Lopez J; Lai-Kwon J; Molife R; Welsh L; Tunariu N; Roda D; Fernández-García P; Lladó V; McNicholl AG; Rosselló CA; Taylor RJ; Azaro A; Rodón J; Sludden J; Veal GJ; Plummer R; Urruticoechea A; Lahuerta A; Mujika K; Escribá PV
Br J Cancer; 2023 Sep; 129(5):811-818. PubMed ID: 37488446
[TBL] [Abstract][Full Text] [Related]
8. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
9. The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.
Erazo T; Lorente M; López-Plana A; Muñoz-Guardiola P; Fernández-Nogueira P; García-Martínez JA; Bragado P; Fuster G; Salazar M; Espadaler J; Hernández-Losa J; Bayascas JR; Cortal M; Vidal L; Gascón P; Gómez-Ferreria M; Alfón J; Velasco G; Domènech C; Lizcano JM
Clin Cancer Res; 2016 May; 22(10):2508-19. PubMed ID: 26671995
[TBL] [Abstract][Full Text] [Related]
10. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
11. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
13. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
15. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
16. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
17. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
[TBL] [Abstract][Full Text] [Related]
18. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
Creemers JHA; Pawlitzky I; Grosios K; Gileadi U; Middleton MR; Gerritsen WR; Mehra N; Rivoltini L; Walters I; Figdor CG; Ottevanger PB; de Vries IJM
BMJ Open; 2021 Nov; 11(11):e050725. PubMed ID: 34848513
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
20. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
